Survodutide vs Liraglutide
A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. A once-daily GLP-1 receptor agonist; an earlier acylated analog. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Survodutide BI 456906 | Liraglutide | |
|---|---|---|
| Also known as | — | Victoza, Saxenda |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Glucagon/GLP-1 dual receptor agonist (acylated peptide) | GLP-1 receptor agonist (acylated, 31 aa) |
| Receptor / target | Glucagon receptor (GCGR) + GLP-1 receptor | GLP-1 receptor (GLP-1R) |
| Molecular weight | ≈4,800 Da | ~3,751.2 Da |
| Half-life | engineered for once-weekly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Survodutide and Liraglutide?
- Survodutide is an engineered analog based on Glucagon-like peptide-1; Liraglutide is an engineered analog based on Glucagon-like peptide-1. Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor; Liraglutide signals at GLP-1 receptor (GLP-1R).
- How do the half-lives of BI 456906 and Liraglutide compare?
- The reported circulating half-life of Survodutide is engineered for once-weekly dosing; Liraglutide is ~13 h. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Liraglutide vs Survodutide. Or open the interactive comparison tool to add more molecules.